News for Veru Inc. (VERU)

Discover Veru Inc's Q1 2025 progress as it transitions into a biopharma focus.

Veru Inc (NASDAQ:VERU) Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations...

Revenue: Reported revenue of $1.28 million, aligning with the estimated revenue for the quarter.Earnings Per Share (EPS): Achieved EPS of -$0.01, surpassing th

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of pr

On December 31, 2024, ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) executed a significant reduction in its holdings of Veru Inc. The firm decreased its

Veru Inc (VERU) is set to release its Q1 2025 earnings on Feb 13, 2025. The consensus estimate for Q1 2025 revenue is $3.02 million, and the earnings are expect

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling over 100 points on Monday. The Dow traded up 0.22% to 44,521.81 while the NASDAQ f...

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index edging higher on Monday. The Dow traded up 0.04% to 44,440.59 while the NASDAQ...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 600 points on Monday. Following the market opening Monday, the Dow traded down 0....

-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.00

**media[524941]**

Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.

SWK Holdings updates on recent financial activities

Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal Condom) business to clients managed by Riva Ridge Capital Management LP and co-investors for $18 million. As a result of the FC2 business sale, Veru’s workforce will be reduced by approximately 90%, from 210 employees to 22. After deducting the change of control premium to SWK Funding LLC under the company's Residual Royalty Agreement, along with customary transaction fees, Ve

**media[503363]**

Veru (VERU) delivered earnings and revenue surprises of 14.29% and 86.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Strong Growth Ahead: Sexual Wellness Market Projected to Reach $29.75 Billion by 2031, Expanding at a CAGR of 4.7% from $21.57 Billion in 2023...

Rapid Advancements of Innovative Antiviral “ COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

The metastatic prostate cancer market is driven by advancements in targeted therapies and immunotherapies, catering to a growing aging population. Early...